Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03119662 · ClinicalTrials.gov registry record · Phase 4
A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease
A Phase 4 study, sponsored by GE Healthcare.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT03119662 is a Phase 4 study that was terminated before completion, run by GE Healthcare. The registered enrollment target is 4 participants.
The verdict
NCT03119662, a Phase 4 study, was terminated before completion, sponsored by GE Healthcare.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
This parallel-group, randomized, placebo-controlled study will examine the incidence and severity of acute kidney injury (AKI) in patients with chronic kidney disease (CKD) stage III/IV following an i.v. injection of iso-osmolar iodinated contrast material iodixanol (Visipaque™ Injection 320 mgI/mL), as compared with patients who received saline and underwent a non-enhanced CT (NECT) and duplex ultrasound (US) during their scheduled post-EVAR surveillance imaging.
Interventions
- DRUG Placebos
- DRUG Visipaque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-02-08 |
| Est. Completion | 2018-10-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03119662
The ClinicalTrials.gov registry entry for NCT03119662 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03119662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03119662 about?
NCT03119662 is a clinical study titled "A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease". This parallel-group, randomized, placebo-controlled study will examine the incidence and severity of acute kidney injury (AKI) in patients with chronic kidney disease (CKD) stage III/IV following an i.v. injection of iso-osmolar iodinated contrast material iodixanol (Visipaque™ Injection 320 mgI/mL)...
What is the current status of trial NCT03119662?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2018-02-08. Estimated completion is 2018-10-19.
What interventions are being tested in trial NCT03119662?
The interventions under investigation include: Placebos (DRUG), Visipaque (DRUG).
Who is sponsoring clinical trial NCT03119662?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.